Related posts
Stocks climb ahead of U.S. MidtermsThis summary was created by AI, based on 7 opinions in the last 12 months.
Viatris (VTRS-Q) is a pharmaceutical company that is currently trading at a low PE ratio of 3-8x earnings. The company has a strong focus on returning value to shareholders through stock buybacks, maintaining a healthy dividend yield, and making strategic acquisitions. Despite some concerns about its acquisition strategy, Viatris is seen as a cash-generating company with growth potential in its new product launches. Overall, the company is viewed as an undervalued player in the pharma industry with a solid dividend yield and potential upside.
Great free cashflow, more than covers the 4% yield. Cheap PE at 4x earnings. Q2 results coming out in early August, where a couple of divestitures will be announced. Awaiting stock buyback. Paying down debt, making acquisitions. $12B market cap, but not well followed.
Stock's done nothing for him except pay a 4% dividend. A couple of more asset sales to go next quarter. He'd love it if they took the cash, paid down debt, and bought back shares. But management keeps making acquisitions, riskier. Trades at 3-4x earnings.
Share price flat, but owns shares.
Excellent business within healthcare sector.
Getting into new business lines.
4% dividend yield with lots of free cash flow.
Share buybacks good for shareholders.
Trading at 4x earnings.
Product of recent merger of two separate pharma business'.
New CEO - remains to be seen whether he will preform.
Would like to see stabilization on business before investing.
Too early to invest.
It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0
Global healthcare, mix of branded drugs and generics. Drug business has had a good run, but there's going to be significant pushback on the outsized profits, both globally and in the US. He prefers medical devices.
Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q
In the last year, 5 stock analysts published opinions about VTRS-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.
Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
5 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.
On 2024-12-04, Viatris (VTRS-Q) stock closed at a price of $13.04.
It is a pharma company trading at 5X earnings. It is buying back stock, as much as 5% and has a slew of new products.